There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...

Allogeneic HSCT achieved 92% sustained, medication-free remission and 100% survival in children with monogenic IBD, highlighting its potential as a transformative treatment. Monogenic IBD, ...

For the roughly 3 million Americans living with inflammatory bowel disease, the current treatment options tell a frustrating story. Anti-TNF biologics such as infliximab and adalimumab, the backbone ...

Representative immunofluorescence images showing the intestinal epithelium of a murine colitis model treated with either PBS or glycyrrhizin, adapted from Figure 2F. Cleaved Caspace-3 (red), EpCAM ...

Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.

Inflammatory bowel disease (IBD) is an umbrella term for Crohn's disease and ulcerative colitis, which both involve chronic inflammation in the digestive tract. IBD affects millions of people and ...

Researchers have developed a stem cell-based model of the human intestine that may transform how new IBD treatments are discovered. After testing thousands of compounds, they identified glycyrrhizin — ...

Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn's disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated.